Video: Who Am I?| Webinar: ACR/CHEST ILD Guidelines in Practice

An official publication of the ACR and the ARP serving rheumatologists and rheumatology professionals

  • Conditions
    • Axial Spondyloarthritis
    • Gout and Crystalline Arthritis
    • Myositis
    • Osteoarthritis and Bone Disorders
    • Pain Syndromes
    • Pediatric Conditions
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Sjögren’s Disease
    • Systemic Lupus Erythematosus
    • Systemic Sclerosis
    • Vasculitis
    • Other Rheumatic Conditions
  • FocusRheum
    • ANCA-Associated Vasculitis
    • Axial Spondyloarthritis
    • Gout
    • Lupus Nephritis
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Sjögren’s Disease
    • Systemic Lupus Erythematosus
  • Guidance
    • Clinical Criteria/Guidelines
    • Ethics
    • Legal Updates
    • Legislation & Advocacy
    • Meeting Reports
      • ACR Convergence
      • Other ACR meetings
      • EULAR/Other
    • Research Rheum
  • Drug Updates
    • Analgesics
    • Biologics/DMARDs
  • Practice Support
    • Billing/Coding
    • EMRs
    • Facility
    • Insurance
    • Technology
      • Information Technology
      • Apps
    • QA/QI
    • Workforce
  • Opinion
    • Patient Perspective
    • Profiles
    • Rheuminations
      • Video
    • Speak Out Rheum
  • Career
    • ACR ExamRheum
    • Awards
    • Career Development
      • Education & Training
    • Certification
  • ACR
    • ACR Home
    • ACR Convergence
    • ACR Guidelines
    • Journals
      • ACR Open Rheumatology
      • Arthritis & Rheumatology
      • Arthritis Care & Research
    • From the College
    • Events/CME
    • President’s Perspective
  • Search

Search results for: drug prices

Two U.S. Lawmakers Probe Marathon over $89,000 Drug Price

Reuters Staff  |  February 14, 2017

WASHINGTON (Reuters)—Two U.S. lawmakers have called on privately held Marathon Pharmaceuticals LLC to explain how it came to price its newly approved drug to treat Duchenne muscular dystrophy at $89,000 a year when patients have for decades been able to acquire it overseas for as little as $1,000. The drug, Emflaza, known generically as deflazacort,…

Filed under:Drug Updates Tagged with:costsdrug pricingpharmaceutical company

U.S. Supreme Court to Hear Dispute Over Biologic Drug Sales

Andrew Chung  |  January 15, 2017

NEW YORK (Reuters)—The U.S. Supreme Court on Friday agreed to hear a dispute over whether companies that make copycat versions of biologic drugs must wait six months after winning federal approval to begin selling them. The justices will take up an appeal by Novartis AG of a 2015 federal appeals court decision that prevented the…

Filed under:Biologics/DMARDsDrug UpdatesLegal Updates Tagged with:BiologicsBiologics & BiosimilarsBiosimilarslawsuitLegalSupreme Court

U.S. Democrats Seek Trump’s Cooperation on Drug Price Reform

Reuters Staff  |  December 22, 2016

NEW YORK (Reuters)—A group of Democratic senators took their plans to tackle rising drug costs to President-Elect Donald Trump on Tuesday, asking him to work with them and Republicans on the issue. In a letter dated Tuesday, the 19 senators named five areas for cooperation: allowing the Medicare program to negotiate prescription prices, increasing transparency,…

Filed under:Drug Updates Tagged with:Affordable Care Act (ACA)costsDrugsMedicareObamacare

U.S. Could File Charges in Generic Drug Probe by Year-End

Reuters Staff  |  November 4, 2016

(Reuters)—U.S. prosecutors could file the first charges in their criminal investigation of generic drugmakers over suspected price collusion by the end of the year, Bloomberg reports. The antitrust investigation by the U.S. Department of Justice (DOJ) spans more than a dozen companies and about two dozen drugs, Bloomberg reports, citing people familiar with the matter….

Filed under:Drug Updates Tagged with:Department of Justicegeneric drugsLegal

Can Anything Contain Drug Costs in the U.S.?

Lisa Rapaport  |  August 23, 2016

(Reuters Health)—The U.S., which spends more on drugs than any other country, might contain costs by limiting market exclusivity for brand name medicines and changing coverage requirements for government health plans, some doctors argue. Although brand-name drugs account for only 10% of all dispensed prescriptions in the U.S., they make up 72% of drug spending,…

Filed under:Drug Updates Tagged with:costsDrugsgeneric drugspharmaceutical companyPharmaceutical Research

U.S. FDA Panel Backs Valeant Psoriasis Drug with Risk Program

Toni Clarke  |  July 21, 2016

(Reuters)—Valeant Pharmaceuticals International Inc.’s experimental drug to treat psoriasis should be approved as long as certain measures are put in place to mitigate the risk of suicide, an advisory committee to the U.S. Food and Drug Administration concluded on Tuesday. The FDA is not obliged to follow the advice of its advisory committees but typically…

Filed under:Biologics/DMARDsDrug Updates Tagged with:brodalumabFDAFood and Drug AdministrationPsoriasisSafety

Sun Pharma Gets U.S. Subpoena over Generic Drugs Pricing

Reuters Staff  |  June 1, 2016

MUMBAI (Reuters)—The U.S. Department of Justice (DOJ) has subpoenaed India’s largest drugmaker Sun Pharmaceutical Industries Ltd. seeking information about the pricing and marketing of the generic drugs it sells in the U.S., the company said on Saturday. The DOJ’s antitrust division has also asked Sun Pharma’s U.S. unit for documents related to employee and corporate records…

Filed under:Drug Updates Tagged with:costsDrugsgeneric drugsIndiaInternational

Roche & Novartis Face Off in Biosimilar Drug Battle

John Miller  |  May 31, 2016

ZURICH (Reuters)—Switzerland’s biggest drugmakers are clashing over cheaper copies of pricey biotech drugs—one reason why Novartis is considering selling its $14 billion stake in cross-town rival Roche. With a copycat of Roche’s blood cancer drug Rituxan (rituximab) pending European approval, Novartis aims to muscle in on a share of sales that last year hit 7…

Filed under:Drug Updates Tagged with:BiosimilarsBusinessgeneric drugsNovartisRemicaderituximabRoche

France Gets G7 to Discuss Global Regulation of Medicine Prices

Matthias Blamont & Jean-Baptiste Vey  |  May 3, 2016

PARIS (Reuters)—France will press its G7 partners this month to launch an “irreversible” process to control the prices of new medicines, part of a global drive to make life-saving drugs more affordable, three sources told Reuters. President Francois Hollande said in March he would push for the international regulation of drugs prices when he meets…

Filed under:Drug UpdatesLegislation & AdvocacyProfessional Topics Tagged with:costsDrugsInternationalpharmaceutical companyTreatment costs

Major Drugmakers Push Back in U.S. Price Debate

Caroline Humer  |  January 15, 2016

SAN FRANCISCO (Reuters)—With a backlash brewing over the price of medicines in the U.S., drugmakers are pushing back with a new message: Most people don’t pay retail. Top executives from Eli Lilly and Co, Merck & Co and Biogen Inc. said in interviews with Reuters this week that the media focus on retail, or “list…

Filed under:Drug Updates Tagged with:costsDrugsOut-of-pocket costsPatient costsPfizer Inc.pharmaceutical company

  • « Previous Page
  • 1
  • …
  • 7
  • 8
  • 9
  • 10
  • 11
  • …
  • 25
  • Next Page »
  • About Us
  • Meet the Editors
  • Issue Archives
  • Contribute
  • Advertise
  • Contact Us
  • Copyright © 2025 by John Wiley & Sons, Inc. All rights reserved, including rights for text and data mining and training of artificial technologies or similar technologies. ISSN 1931-3268 (print). ISSN 1931-3209 (online).
  • DEI Statement
  • Privacy Policy
  • Terms of Use
  • Cookie Preferences